Erythropoietic and bone marrow stimulating activity of terminalia catappa extract: Possible role of nitric oxide signaling.

Aims: We assessed the capacity and mechanism of Terminalia catappa (TC) to induce erythropoiesis in vivo in phenylhydrazine- induced anemic mice. Place and Duration of Study: Sample: This study was carried out at Department of Biochemistry and Center for Biotechnology Research and Training Ahmadu Bello University Zaria, and National Research Institute for Chemical Technology, Zaria. The duration spanned between Jan 2011 and Feb 2012. Methodology: Solvent fractions of Terminalia catappa aqueous extract was used to treat phynylhydrazine-induced anemic mice. Treatment was done for four days, erythropoietic activity of each fraction was assayed by determining the effect of these fractions on intracellular hemoglobin and reticulocyte level from the blood, arginase was also assayed. Bone marrow carbonic anhydrase was assayed to monitor bone marrow erythropoietic stimulation. Results: Terminalia catappa was able to up-regulate the synthesis of intracellular hemoglobin (0.135 ±0.004 μmol/0.1ml) significantly comparable to hydroxyurea (HU) (0.158±0.006 μmol/0.1ml), and normalize the peripheral blood reticulocyte index significantly at P<.05 0.94±0.25% close to the non anemic mice 0.97±0.25% and bone marrow carbonic anhydrase activity. TC inhibited arginase activity significantly (P<.05) comparable to hydroxyurea. Conclusion: The results demonstrate Terminalia catappa extract as an erythropoietic agent that supports normal erythroid differentiation in vivo in phenylhydrazine- induced anemic mice in a synergistic fashion.

Molecular epidemiology of hepatitis C virus (HCV) in Kadun State

Objective: To determine the distribution of hepatitis C virus (HCV) genotypes and subtypes among blood donors and outpatients attendees positive for antibody to HCV (anti-HCV). Justification: Hepatitis C virus (HCV) continues to be a major disease burden on the world and Man is the only known natural host of Hepatitis C virus (Chivaliez and Pawlotsky; 2007). There is no published data on the prevalence of the genotypes and subtypes of HCV in Kaduna State. Setting: Three hospitals one in each of the 3 senatorial zones in Kaduna State. Patients: Blood donors who reported for blood donation and outpatient department attendees. Method: Antibody detection by a third generation HCV ELISA (Biotech Laboratories; UK); HCV RNA and genotyping by Reverse Transcriptase polymerase chain reaction with genotype-specific primers. (Sacace Biotechnologies; UK). Results: of the 259 plasma specimens screened for Hepatitis C virus in this study; 20(7.7) were positive for anti-HCV antibodies by ELISA and 16(6.2) of the antibodies positive specimen were positive for HCV RNA. Of the 139 blood donors tested; 8 (5.8) were HCV RNA positive. Similarly; 120 were tested from the outpatient Department attendees and 8 (6.7) were HCV RNA positive. Hepatitis C virus genotype 1b was found in the entire HCV RNA positive sample. Conclusions: The findings of 6.2prevalence of HCV infection based on HCV RNA test confirmed that there is Hepatitis C virus in Kaduna State with genotype 1b as the predominant genotype found in all the three senatorial zones

Seroprevalence of hepatitis C virus antibodies amongst blood donors in Ahmadu Bello University Teaching Hospital (ABUTH) Kaduna

Background: Hepatitis C virus (HCV) is one of the most common transfusion transmissible infections hence the introduction of routine screening for its antibodies in blood donors in most blood banks. Methods: This was a retrospective study in which the blood donor screening register for all intending donors were reviewed and analyzed. Results: There were 4;731 potential donors with age range 20-41years. Eighty six (1.8) were sero-positive to HCV antibodies with a decreasing incidence over the period under review. The highest incidence was recorded the age group 31-40 years. Aim: To determine the sero-prevalence of HCV among blood donors in ABUTH Kaduna. Conclusion: HCV infection is not uncommon in our environment hence the need to emphasize it's routine screening among all potential donors

Severe Depression Following a-interferon Usage in a Patient with Chronic Myeloid Leukemia

Background: Chronic myeloid leukaemia (CML); with a median age of 40 years; is one of the commonest haematological malignancies in Nigeria. Cytoreductive agents; which were hitherto the mainstay of treatment; neither induce cytogenetic nor haematologic remission. Alpha-interferon (a-IFN); an endogenous glycoprotein with cytotoxic and natural killer cell enhancer effects has been found to induce haematologic and cytogenetic remission in patients with CML; but neuro- psychiatric complications of a -interferon (a-IFN) usage were not reported in Nigeria. Objective: To report a case of deliberate self-harm in University Lecturer as a side effect of a-IFN in the treatment of CML. Method: Clinical and laboratory follow up of a patient receiving a-IFN in the management of CML from the time of diagnosis of CML to the point of loss of contact. Result: Severe depression is a complication that may adversely influence the clinical outcome of a-IFN usage Conclusions/Recommendations: Although interferon related depression is uncommon; it is suggested that pre-therapy interferon assays and neuro-psychiatric assessment are carried out in prospective users of a-IFN